ANDA 78180, held by Sagent Pharms. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 78180 (Ondansetron Hydrochloride), held by Sagent Pharms, was first approved by FDA on Mar 26, 2007, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 26, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Discontinued |
| Nov 30, 2015 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 26, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters